|
MechanismH1 receptor antagonists [+1] |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.South Korea |
First Approval Date14 Apr 2025 |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.South Korea |
First Approval Date01 Apr 2025 |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.South Korea |
First Approval Date25 Oct 2024 |
100 Clinical Results associated with CorePharm Co., Ltd.
0 Patents (Medical) associated with CorePharm Co., Ltd.
100 Deals associated with CorePharm Co., Ltd.
100 Translational Medicine associated with CorePharm Co., Ltd.